Efficacy and safety of lenvatinib for patients with advanced or recurrent thymic carcinoma: A real-world retrospective study
Not Applicable
Recruiting
- Conditions
- nresectable advanced or recurrent thymic carcinoma
- Registration Number
- JPRN-UMIN000051645
- Lead Sponsor
- Graduate School of Medicine, Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have expressed their refusal to participate in this study through an information disclosure document
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method